哮喘的新生物标志物。

IF 2.8 3区 医学 Q2 RESPIRATORY SYSTEM
Current Opinion in Pulmonary Medicine Pub Date : 2025-05-01 Epub Date: 2025-02-14 DOI:10.1097/MCP.0000000000001155
Nikita Agrawal, Monica Kraft
{"title":"哮喘的新生物标志物。","authors":"Nikita Agrawal, Monica Kraft","doi":"10.1097/MCP.0000000000001155","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Asthma is a common global respiratory disease characterized by airway inflammation. It is a heterogenous group of disorders with overlapping biological mechanisms. This review will discuss the current state of the use of biomarkers in asthma with an eye to the future. The identification of biomarkers has advanced our understanding of inflammatory pathways in asthma and aided in development of targeted therapies. However, even with similar inflammatory biomarkers, not all patients respond uniformly. Thus, further research into novel biomarkers in asthma is needed.</p><p><strong>Recent findings: </strong>Recent literature highlights several key themes in biomarker research for asthma. Biomarkers can be derived from various sources, including sputum, blood, urine, and exhaled breath. Historically, studies have focused on eosinophilic inflammation, yet total blood eosinophil counts do not capture asthma pathology and treatment responses. Recent investigations explore eosinophil activity as well as eosinophil subpopulations based on surface protein expressions. Mast cell involvement, their mediators, and club cell secretory protein are further being examined across different asthma molecular phenotypes.</p><p><strong>Summary: </strong>The complexity of inflammatory pathways in asthma, influenced by various factors, underscores the inadequacy of relying on a single biomarker at one time point. Continued research is essential to identify appropriate biomarkers.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"243-250"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Novel biomarkers in asthma.\",\"authors\":\"Nikita Agrawal, Monica Kraft\",\"doi\":\"10.1097/MCP.0000000000001155\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Asthma is a common global respiratory disease characterized by airway inflammation. It is a heterogenous group of disorders with overlapping biological mechanisms. This review will discuss the current state of the use of biomarkers in asthma with an eye to the future. The identification of biomarkers has advanced our understanding of inflammatory pathways in asthma and aided in development of targeted therapies. However, even with similar inflammatory biomarkers, not all patients respond uniformly. Thus, further research into novel biomarkers in asthma is needed.</p><p><strong>Recent findings: </strong>Recent literature highlights several key themes in biomarker research for asthma. Biomarkers can be derived from various sources, including sputum, blood, urine, and exhaled breath. Historically, studies have focused on eosinophilic inflammation, yet total blood eosinophil counts do not capture asthma pathology and treatment responses. Recent investigations explore eosinophil activity as well as eosinophil subpopulations based on surface protein expressions. Mast cell involvement, their mediators, and club cell secretory protein are further being examined across different asthma molecular phenotypes.</p><p><strong>Summary: </strong>The complexity of inflammatory pathways in asthma, influenced by various factors, underscores the inadequacy of relying on a single biomarker at one time point. Continued research is essential to identify appropriate biomarkers.</p>\",\"PeriodicalId\":11090,\"journal\":{\"name\":\"Current Opinion in Pulmonary Medicine\",\"volume\":\" \",\"pages\":\"243-250\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Pulmonary Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MCP.0000000000001155\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCP.0000000000001155","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

综述目的:哮喘是一种以气道炎症为特征的全球常见呼吸系统疾病。它是一组具有重叠生物学机制的异质性疾病。这篇综述将讨论生物标志物在哮喘中的应用现状,并着眼于未来。生物标志物的鉴定提高了我们对哮喘炎症途径的理解,并有助于靶向治疗的发展。然而,即使具有相似的炎症生物标志物,也不是所有患者的反应都一致。因此,需要进一步研究哮喘的新型生物标志物。最近的发现:最近的文献强调了哮喘生物标志物研究的几个关键主题。生物标志物可以从各种来源获得,包括痰、血液、尿液和呼出的气体。历史上,研究主要集中在嗜酸性粒细胞炎症,但总血嗜酸性粒细胞计数不能捕获哮喘病理和治疗反应。最近的研究探讨了基于表面蛋白表达的嗜酸性粒细胞活性以及嗜酸性粒细胞亚群。肥大细胞的参与、它们的介质和俱乐部细胞分泌蛋白在不同的哮喘分子表型中被进一步研究。摘要:哮喘炎症通路的复杂性,受各种因素的影响,强调了在一个时间点依赖单一生物标志物的不足。持续的研究对于确定合适的生物标志物至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Novel biomarkers in asthma.

Purpose of review: Asthma is a common global respiratory disease characterized by airway inflammation. It is a heterogenous group of disorders with overlapping biological mechanisms. This review will discuss the current state of the use of biomarkers in asthma with an eye to the future. The identification of biomarkers has advanced our understanding of inflammatory pathways in asthma and aided in development of targeted therapies. However, even with similar inflammatory biomarkers, not all patients respond uniformly. Thus, further research into novel biomarkers in asthma is needed.

Recent findings: Recent literature highlights several key themes in biomarker research for asthma. Biomarkers can be derived from various sources, including sputum, blood, urine, and exhaled breath. Historically, studies have focused on eosinophilic inflammation, yet total blood eosinophil counts do not capture asthma pathology and treatment responses. Recent investigations explore eosinophil activity as well as eosinophil subpopulations based on surface protein expressions. Mast cell involvement, their mediators, and club cell secretory protein are further being examined across different asthma molecular phenotypes.

Summary: The complexity of inflammatory pathways in asthma, influenced by various factors, underscores the inadequacy of relying on a single biomarker at one time point. Continued research is essential to identify appropriate biomarkers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
109
审稿时长
6-12 weeks
期刊介绍: ​​​​​​Current Opinion in Pulmonary Medicine is a highly regarded journal offering insightful editorials and on-the-mark invited reviews, covering key subjects such as asthma; cystic fibrosis; infectious diseases; diseases of the pleura; and sleep and respiratory neurobiology. Published bimonthly, each issue of Current Opinion in Pulmonary Medicine introduces world renowned guest editors and internationally recognized academics within the pulmonary field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信